The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study
Open accessAbstract
Background: Little is known about statins in the prevention of dyslipidaemia induced renal function decline. The secondary coronary heart disease (CHD) prevention GREACE study suggested that dose titration with atorvastatin (10–80 mg/day, mean dose 24 mg/day) achieves the national cholesterol educational programme treatment goals and significantly reduces morbidity and mortality, compared with usual care. Aims: To report the effect of statin on renal function compared with untreated dyslipidaemia in both treatment groups. Methods/Results: All patients had plasma creatinine values within the reference range < 115 µmol/litre (13 mg/litre). The on study creatinine clearance (CrCl), as estimated (for up to 48 months) by the Cockroft-Gault formula, was compared within and between treatment groups using analysis of variance to assess differences over time. Patients from both groups not treated with statins (704) showed a 5.2% decrease in CrCl (p < 0.0001). Usual care patients on various statins (97) had a 4.9% increase in CrCl (p = 0.003). Structured care patients on atorvastatin (783) had a 12% increase in CrCl (p < 0.0001). This effect was more prominent in the lower two quartiles of baseline CrCl and with higher atorvastatin doses. After adjustment for 25 predictors of all CHD related events, multivariate analysis revealed a hazards ratio of 0.84 (confidence interval 0.73 to 0.95; p = 0.003) with every 5% increase in CrCl. Conclusions: In untreated dyslipidaemic patients with CHD and normal renal function at baseline, CrCl declines over a period of three years. Statin treatment prevents this decline and significantly improves renal function, potentially offsetting an additional factor associated with CHD risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Simvastatin, an HMG–Coenzyme A Reductase Inhibitor, Improves Endothelial Function Within 1 Month
O'Driscoll, G., Green, D., & Taylor, R. R. (1997) · Circulation · doi:10.1161/01.cir.95.5.1126 · Cited by 952
Effect of lipid reduction on the progression of renal disease: A meta-analysis
Fried, L. F., Orchard, T. J., & Kasiske, B. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00487.x · Cited by 672
Athyros, V. G., Papageorgiou, A. A., Mercouris, B. R., Athyrou, V. V., Symeonidis, A. N., Basayannis, E. O., Demitriadis, D. S., & Kontopoulos, A. G. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000787 · Cited by 533
Self-citationCholesterol and the risk of renal dysfunction in apparently healthy men
Schaeffner, E. S., Kurth, T., Curhan, G. C., Glynn, R. J., Rexrode, K. M., Baigent, C., Buring, J. E., & Gaziano, J. M. (2003) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1482084 · Cited by 442
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats
Kasiske, B. L., O'donnell, M. P., Cleary, M. P., & Keane, W. F. (1988) · Kidney International · doi:10.1038/ki.1988.51 · Cited by 409
Heart Protection Study Collaborative Group (2011) · The Lancet · doi:10.1016/s0140-6736(11)61125-2 · Cited by 373
Bianchi, S., Bigazzi, R., Caiazza, A., & Campese, V. M. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50140 · Cited by 332
Focal and segmental glomerulosclerosis: Analogies to atherosclerosis
Diamond, J. R., & Karnovsky, M. J. (1988) · Kidney International · doi:10.1038/ki.1988.87 · Cited by 330
Kasiske, B. L., O'Donnell, M. P., Garvis, W. J., & Keane, W. F. (1988) · Circulation Research · doi:10.1161/01.res.62.2.367 · Cited by 291
Low-density lipoprotein-independent effects of statins
Davignon, J., & Laaksonen, R. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199912000-00010 · Cited by 244
Effects of hypertension and dyslipidemia on the decline in renal function
Mänttäri, M., Tiula, E., Alikoski, T., & Manninen, V. (1995) · Hypertension · doi:10.1161/01.hyp.26.4.670 · Cited by 229
Effects of Fibrates on Serum Metabolic Parameters
Elisaf, M. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000516 · Cited by 164
Self-citationEarly vascular benefits of statin therapy
Tsiara, S., Elisaf, M., & Mikhailidis, D. P. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002225 · Cited by 157
Self-citationHarris, K. P. G., Purkerson, M. L., Yates, J., & Klahr, S. (1990) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80587-7 · Cited by 146
Huggins, G. S., Pasternak, R. C., Alpert, N. M., Fischman, A. J., & Gewirtz, H. (1998) · Circulation · doi:10.1161/01.cir.98.13.1291 · Cited by 134
Kaplan, R. C., Heckbert, S. R., Furberg, C. D., & Psaty, B. M. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00405-5 · Cited by 126
The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
Mikhailidis, D. P., & Wierzbicki, A. S. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000778 · Cited by 124
Self-citationLipids and progressive kidney disease.
Moorhead, J. F. (1991) · PubMed · Cited by 91
Protective Effect of HMG-CoA Reductase Inhibitor on Experimental Renal Ischemia-Reperfusion Injury
Yokota, N., O’Donnell, M. A., Daniels, F. X., Burne-Taney, M. J., Keane, W. F., Kasiske, B. L., & Rabb, H. (2002) · American Journal of Nephrology · doi:10.1159/000066301 · Cited by 91
Lovastatin Retards the Progression of Established Glomerular Disease in Obese Zucker Rats
O’Donnell, M. P., Kasiske, B. L., Kim, Y., Schmitz, P. G., & Keane, W. F. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70172-5 · Cited by 91
Early glomerular changes in rats with dietary-induced hypercholesterolemia
Guijarro, C., Kasiske, B. L., Kim, Y., O’Donnell, M. P., Lee, H. S., & Keane, W. F. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90169-8 · Cited by 89
Hyperlipidemia and the progression of renal disease
Keane, W. F., Kasiske, B. L., & Mp, O. (1988) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/47.1.157 · Cited by 87
Athyros, V. G., Papageorgiou, A. A., Symeonidis, A. N., Didangelos, T. P., Pehlivanidis, A. N., Bouloukos, V. I., & Mikhailidis, D. P. (2003) · Angiology · doi:10.1177/000331970305400607 · Cited by 85
Self-citationElisaf, M., & Mikhailidis, D. P. (2002) · Angiology · doi:10.1177/000331970205300501 · Cited by 85
Self-citationJoyce, M., Kelly, C. J., Winter, D. C., Chen, G., Leahy, A. L., & Bouchier‐Hayes, D. M. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6256 · Cited by 77
Youssef, F., Gupta, P., Seifalian, A. M., Myint, F., Mikhailidis, D. P., & Hamilton, G. (2004) · Angiology · doi:10.1177/000331970405500108 · Cited by 75
Self-citationThe Early Effect of Lipid-lowering Treatment on Carotid and Femoral Intima Media Thickness (IMT)
Youssef, F., Seifalian, A. M., Jagroop, I. A., Myint, F., Baker, D., Mikhailidis, D. P., & Hamilton, G. (2002) · European Journal of Vascular and Endovascular Surgery · doi:10.1053/ejvs.2002.1611 · Cited by 71
Self-citationMassy, Z. A., Kim, Y., Guijarro, C., Kasiske, B. L., Keane, W. F., & O’Donnell, M. P. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1992 · Cited by 68
Statins and renal function in patients with diabetes mellitus
Athyros, V. G., Papageorgiou, A. A., Elisaf, M., Mikhailidis, D. P., & on Behalf of the GREACE Study Collaborative Group (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002315 · Cited by 60
Self-citationLipids, protein intake, and diabetic nephropathy.
Gin, H., Rigalleau, V., & Aparicio, M. (2000) · PubMed · Cited by 38
Yamashita, T., Kawashima, S., Miwa, Y., Ozaki, M., Namiki, M., Hirase, T., Inoue, N., Hirata, K., & Yokoyama, M. (2002) · Journal of Hypertension · doi:10.1097/00004872-200212000-00027 · Cited by 36
Sinzinger, H. F., Kritz, H., & Furberg, C. D. (2003) · PubMed · Cited by 26
Athyros, V. G., Mikhailidis, D. P., Papageorgiou, A. A., Mercouris, B. R., Athyrou, V. V., Symeonidis, A. N., Basayannis, E. O., Demitriadis, D. S., & Kontopoulos, A. G. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001317 · Cited by 23
Self-citationEffect of Atorvastatin on Serum Creatinine Levels
Kakafika, A. I., Liamis, G. L., Elisaf, M., et al. (2001) · Current Medical Research and Opinion · doi:10.1185/0300799039117071 · Cited by 22
Self-citationThe Role of Lipids in Progressive Glomerular Disease
Keane, W. F., Kasiske, B. L., & O’Donnell, M. P. (1987) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5445-1_11 · Cited by 13
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Velussi, M. (2002) · PubMed · Cited by 10
Cited by
Athyros, V. G., Tziomalos, K., Gossios, T. D., Griva, T., Anagnostis, P., Kargiotis, K., Pagourelias, E. D., Theocharidou, E., Karagiannis, A., & Mikhailidis, D. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61272-x · Cited by 685
Self-citationRisk factors for chronic kidney disease in a community-based population: a 10-year follow-up study
Yamagata, K., Ishida, K., Sairenchi, T., Takahashi, H., Ohba, S., Shiigai, T., Narita, M., & Koyama, A. (2007) · Kidney International · doi:10.1038/sj.ki.5002017 · Cited by 624
Statins for Improving Renal Outcomes: A Meta-Analysis
Sandhu, S., Wiebe, N., Fried, L. F., & Tonelli, M. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010012 · Cited by 478
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370
Metadata
- Authors
- Athyros, V. G., Mikhailidis, D. P., Papageorgiou, A. A., Symeonidis, A. N., Pehlivanidis, A. N., Bouloukos, V. I., & Elisaf, M.
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2004-06-25
- Volume
- 57
- Issue
- 7
- Pages
- 728-734
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W1981155050
- Cited by
- 353
- References
- 46
- FWCI
- 31.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.